Mild Dementia/Alzheimer's Disease

  • STATUS
    Recruiting
  • sponsor
    Actinogen Medical
Updated on 8 December 2020

Summary

Mild Dementia/Alzheimer's Disease

Description

Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in your body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Alzheimer's disease. This will be assessed by completing a series of assessments where you will be asked questions by the study staff and you will be asked to write down or verbally say the answers.

The design of the study is double-blind, randomized and placebo controlled. A "double blind" study means that the study doctor and the participants who take part won't know which group is administered the study medication and which group is administered placebo. You will not have to stop taking any medications you are currently taking for your cognitive symptoms such as memantine or donepezil; however, you must be on a stable dose or 3 months.

Details
Clinical Study IdentifierTX152629
SponsorActinogen Medical
Last Modified on8 December 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 50 yrs and 0 yrs?
Gender: Male or Female
Male and Females 50 years or older
Must be willing and able to comply with the requirements of the study
Have a consenting study partner who spends an average of 10 hours/week in contact with the participant and would be able to accompany the participant to all study visits

Exclusion Criteria

Have other neurological disease such as Parkinson’s disease, Huntington’s disease, normal pressure hydrocephalus, brain tumor
Has had a stroke within the last year
A diagnosis of a psychiatric disorder. This includes but is not limited to schizophrenia, schizoaffective disorder, bipolar affective disorder, alcohol dependence syndrome or major depressive disorder
Inability to communicate well with the investigator, poor mental development or impaired cerebral function
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note